Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
State Street SPDR S&P Biotech ETF
(NY:
XBI
)
165.73
UNCHANGED
Streaming Delayed Price
Updated: 8:00 PM EDT, Aug 21, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about State Street SPDR S&P Biotech ETF
< Previous
1
2
...
10
11
12
13
14
15
16
17
Next >
Do Crispr And Vertex Have A 'Functional Cure' For Blood Diseases?
↗
June 13, 2022
Crispr and Vertex tested their gene-edited drug in two blood diseases.
Via
Investor's Business Daily
“Chip Shot” Stock Market (And Sentiment Results)
↗
June 02, 2022
Chips are the key to the economy/inflation moving forward. They are also the key to one of our major new positions in an auto-supplier
Via
Talk Markets
3 Biotech Stocks to Buy Before They Boom
↗
June 01, 2022
It could be a “never-before, never-after opportunity” to buy into these biotech stocks that trade at very attractive valuations.
Via
InvestorPlace
Again, Buy ‘Em
↗
May 31, 2022
Today we discuss again why it’s time to start adding back risk. We cover the major breadth thrusts that fired, some great monthly charts, and more.
Via
Talk Markets
As COVID Subsidies, Here are 8 Infectious Diseases That Could Emerge As Potent Threats
↗
May 30, 2022
The COVID-19 pandemic that emerged in early 2020 doesn't seem to have run its course. Daily average cases, though have declined notably, stood at 110,084 in the U.S. as of Thursday, according to data...
Via
Benzinga
The “Shake It Off” Stock Market (And Sentiment Results)
↗
April 07, 2022
We may be close to a short term peak in yields – bottom in bonds
Via
Talk Markets
PreMarket Prep: Looking For Biotech Bargains With This Wedbush Analyst
↗
May 25, 2022
Biotechnology is one sector that peaked ahead of the S&P 500 index. While the S&P 500 index did not peak until January, the SPDR Biotech (NYSE: XBI) peaked in February 2021 and is now 60% lower than...
Via
Benzinga
This Biotech Looks Good With Increased M&A activity
↗
May 20, 2022
Fierce Biotech backs this up: “Biopharmas have $1.7 trillion to spend on deals this year, and big players like Novartis, Pfizer and Merck & Co. have made it pretty clear they’re on the hunt for...
Via
Talk Markets
The “Mystery Liquidator Revealed” Stock Market (And Sentiment Results)
↗
May 19, 2022
In this week’s AAII Sentiment Survey result, Bullish Percent ticked up a hair to 26% this week from 24.3% last week. Bearish Percent rose to 50.4% from 49%.
Via
Talk Markets
Large Cap Biopharmaceuticals: Provide Growth, Value And Yield
↗
May 16, 2022
Now that all major biopharmaceutical earnings are in, we can review the financial metrics and see if our portfolio needs re-balancing.
Via
Talk Markets
When Will The Stock Market Stop Falling?
↗
May 12, 2022
Stocks have fallen dramatically just this past week, is a bottom near?
Via
Talk Markets
Stocks Tank On May 11 With No Bottom In Sight
↗
May 11, 2022
Despite the sharp decline, the VIX finished down on the day at 32.5. It tells us there was “real” selling in the market today.
Via
Talk Markets
7 Biotech Stocks With Key Catalysts for May
↗
May 11, 2022
The beaten-down state of biotech stocks is a major pulling point for investors who are aiming for market-leading returns.
Via
InvestorPlace
Should Biotech Be On The Critical List?
↗
May 11, 2022
The risk-off market has played havoc with the biotechs where the fundamentals have not changed as much as the valuation.
Via
Talk Markets
“Threading The Needle” Stock Market (And Sentiment Results)
↗
May 05, 2022
Two weeks ago AAII sentiment survey dropped to a 30 year low at 15.8% bullish. Last week it ticked up modestly to 16.4%.
Via
Talk Markets
7 Monster Stock Market Predictions For The Week Of April 25
↗
April 23, 2022
The week ending April 22 was brutal. The S&P 500 fell by nearly 2.75%, but things were much worse than that. Powell unleashed hell when he noted that a 50 bps rate hike was on the table for the FOMC...
Via
Talk Markets
The “magic Chart” Stock Market (And Sentiment Results)
↗
April 21, 2022
We have now come to a point Where the market has priced in more rate hikes than are likely to occur.
Via
Talk Markets
4 Undervalued Biotech Stocks to Add to Your Buy List
↗
April 20, 2022
These biotech stocks have seen their valuations tumble in the year-to-date sell-off. But they have the wherewithal to bounce big and generate decent, market-beating returns.
Via
InvestorPlace
Healthcare Stocks Lead the Way Up as the Market Fades
↗
April 11, 2022
With inflation and energy costs soaring, the Fed ever threatening with higher rates and headlines from the war in Ukraine investors are seeking more defensive positions.
Via
Talk Markets
Recession Fears are Creating a Golden Opportunity for Biotech Stocks
↗
April 08, 2022
Biotech stocks are hard for novice investors to successfully profit from, but it's worth your time to learn the techniques now.
Via
InvestorPlace
Layoffs at Bluebird Bio Highlight the Current Struggles of Biotech Picks
↗
April 08, 2022
Cash will be king in biotech picks like BLUE stock as governments slow approvals and reimbursements of new gene therapies.
Via
InvestorPlace
Sunshine Biopharma Stock Triples on Positive mRNA Cancer Treatment Results
↗
April 05, 2022
SBFM stock tripled to $6.53 on Tuesday after revealing that two of its newly designed mRNA molecules are effective in destroying cancer cells.
Via
InvestorPlace
Good Entry Point for Biotech Stocks
↗
April 04, 2022
Life science and biotech stocks had a good week with the most well-known ETFs up 3-4% for the week and off recent bottoms.
Via
Talk Markets
CNBC's Final Call: Newmont, Biotech ETF And This Energy Stock
↗
April 04, 2022
On CNBC's "The Final Call," Carter Worth recommended Newmont Corporation (NYSE: NEM). The stock has jumped almost 36% year to date.
Via
Benzinga
Acadia: Helping With Alzheimers And Parkinsons
↗
April 03, 2022
Things always change fast in biotech, but until recently things have been moving consistently to the downside. It’s been a while, but we believe this is finally over. And we believe Acadia...
Via
Talk Markets
Biotech Funds and ETFs Continue to Lag
↗
March 28, 2022
It’s no secret that market sectors driving inflation are leading the market. With the US economy still strong and the War in Ukraine limiting supply of nat gas and raw materials, producer costs are...
Via
Talk Markets
How do Biotechnology Funds and ETFs Perform Over Five Years?
↗
March 21, 2022
Biotech investing can be difficult for short-term traders but can offer good returns over five years if balanced with other healthcare positions like the XLV.
Via
Talk Markets
AskSlim Market Week - Friday, March 18
↗
March 18, 2022
Technical and cycle analysis, and market commentary.
Via
Talk Markets
3 Market ETF Stocks to Buy This Week on Fed Jitters
↗
March 14, 2022
The bears have two major tailwinds and the Fed is one. Here are 3 ETF stocks to buy into a potential relief rally after the event blows over.
Via
InvestorPlace
Tough Slogging Ahead for Investors, Diversification is Important
↗
March 07, 2022
Speculative small/mid-cap biotech stocks hit new lows this past week with the XBI at a “triple bottom” about the $84 level only 10 points above the March 2020 lows.
Via
Talk Markets
< Previous
1
2
...
10
11
12
13
14
15
16
17
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.